High biochemical remission rates in patients with primary biliary cholangitis treated with “triple” anticholestatic therapy
Our data confirm that FXR-PPAR-UDCA triple therapy significantly improves ALP with normalization for 30% of patients with PBC at 6 months.
Authors
- Aliya Gulamhusein (ORCID: https://orcid.org/0000-0003-4648-4736)
- Kristel Leung (ORCID: https://orcid.org/0000-0002-1161-4118)
- Gideon M. Hirschfield (ORCID: https://orcid.org/0000-0002-6736-2255)
- Bettina E. Hansen (ORCID: https://orcid.org/0000-0001-8307-3341)
- Inbal Houri (ORCID: https://orcid.org/0000-0002-6397-6604)
- Guilherme Grossi Lopes Cançado (ORCID: https://orcid.org/0000-0002-7824-2152)
- Madeline Cameron (ORCID: https://orcid.org/0009-0000-1183-5386)
- Bo Chen (ORCID: https://orcid.org/0009-0009-6782-5203)
Institutions
- University Health Network (CA)
- Queen's University (CA)
- Toronto General Hospital (CA)
- Erasmus MC (NL)
- Hospital das Clínicas da Universidade Federal de Minas Gerais (BR)
Publication Details
- Journal
- Hepatology Communications
- Published
- 2025-09-29
- DOI
- https://doi.org/10.1097/hc9.0000000000000798
- Primary Topic
- Liver Diseases and Immunity
- Type
- article
- Field-Weighted Citation Impact
- 0.00